Atrasentan
Overview
Atrasentan is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL9194).
API suppliers (1)
Suppliers of Atrasentan evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
1 of 1 holds a GMP certificate on record in the EU or UK registers
- Catalent Pharma Solutions, Inc.United States GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Atrasentan expires 25 Mar 2043 and exclusivity 2 Apr 2030. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
- Canonical SMILES
- CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4
- InChIKey
- MOTJMGVDPWRKOC-QPVYNBJUSA-N
Do you supply Atrasentan? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.